Skip to main content
Frontiers in Medicine logoLink to Frontiers in Medicine
. 2022 Jul 22;9:930217. doi: 10.3389/fmed.2022.930217

Neurological Manifestations of SARS-CoV-2 Infection: Protocol for a Sub-analysis of the COVID-19 Critical Care Consortium Observational Study

Denise Battaglini 1,2,*, Lavienraj Premraj 3,4, Matthew Griffee 5, Samuel Huth 4,6, Jonathon Fanning 4,6, Glenn Whitman 7, Diego Bastos Porto 8, Rakesh Arora 9,10, Lucian Durham 11, Eric Gnall 12,13, Marcelo Amato 14, Virginie Williams 15, Alexandre Noel 15, Sabrina Araujo De Franca 15, Gordan Samoukovic 16, Bambang Pujo 17, David Kent 18, Eva Marwali 19, Abdulrahman Al-Fares 20,21, Stephanie-Susanne Stecher 22, Mauro Panigada 23, Marco Giani 24,25, Giuseppe Foti 24,25, Paolo Pelosi 1,26, Antonio Pesenti 23,27, Nicole Marie White 28, Gianluigi Li Bassi 4,6,29, Jacky Suen 4, John F Fraser 4,30, Chiara Robba 1,26,, Sung-Min Cho 7,, the COVID-19 Critical Care Consortium
PMCID: PMC9355612  PMID: 35935771

Abstract

Introduction

Neurological manifestations and complications in coronavirus disease-2019 (COVID-19) patients are frequent. Prior studies suggested a possible association between neurological complications and fatal outcome, as well as the existence of potential modifiable risk factors associated to their occurrence. Therefore, more information is needed regarding the incidence and type of neurological complications, risk factors, and associated outcomes in COVID-19.

Methods

This is a pre-planned secondary analysis of the international multicenter observational study of the COVID-19 Critical Care Consortium (which collected data both retrospectively and prospectively from the beginning of COVID-19 pandemic) with the aim to describe neurological complications in critically ill COVID-19 patients and to assess the associated risk factors, and outcomes. Adult patients with confirmed COVID-19, admitted to Intensive Care Unit (ICU) will be considered for this analysis. Data collected in the COVID-19 Critical Care Consortium study includes patients' pre-admission characteristics, comorbidities, severity status, and type and severity of neurological complications. In-hospital mortality and neurological outcome were collected at discharge from ICU, and at 28-days.

Ethics and Dissemination

The COVID-19 Critical Care Consortium main study and its amendments have been approved by the Regional Ethics Committee of participating sites. No further approval is required for this secondary analysis.

Trial Registration Number

ACTRN12620000421932.

Keywords: COVID-19, neurological complications, disability, stroke, neurological outcome

Introduction

Coronavirus disease 2019 (COVID-19) presents with a wide spectrum of symptoms, from mild to severe, up to sequential organ failure and multiple-organ dysfunction (1). Reports of neurological manifestations associated with COVID-19 are increasing in the literature (2, 3). COVID-19 neurological signs can involve either the central nervous system (CNS), peripheral nervous system (PNS), or musculoskeletal system. Fatigue, myalgia, impaired sense of smell and taste, and headache are common neurological manifestations of COVID-19 (4, 5), whereas dizziness, confusion, delirium, agitation, stroke, hypoxic ischemic injury, seizures, encephalitis and coma among others have been reported neurological complications of hospitalized patients (4, 5). In some cases, neurological manifestations have been reported even without a primary respiratory involvement (4, 5). Several explanations have been proposed for the cause of neurological symptoms of COVID-19, but the underlying pathophysiology is not well defined. Putative mechanisms include viral neurotropism, a hyperinflammatory and hypercoagulable state, or pathological brain–lung crosstalk (6). Endothelial dysregulation (79) and pro-thrombotic state (1012) have been widely suspected to be the possible main contributors of the increased risk of neurologic events. Indeed, COVID-19 patients are at high risk of hypoxia, hypotension, and microvascular abnormalities (1315) which can promote neuroinflammation and excitotoxicity and increased permeability of the blood brain barrier (16). The risk is even more increased by the use of extracorporeal membrane oxygenation (ECMO) support that is a salvage option in COVID-19 critically ill patients with refractory hypoxemia (17). Prior studies suggested a possible association between neurological complications and mortality (18), but more information is required to delineate this association with respect to regional variation, as well as the risk factors associated to the occurrence of neurological complications (19). The aim of this study is to estimate the incidence of neurological complications in critically ill COVID-19 patients. Associations between neurological complications, patient-level variables and outcomes will also be assessed.

Methods and Analysis

Study Design

This is a pre-planned sub-analysis of a large international multicenter observational study of patients in participating intensive care units (ICUs) with COVID-19 of the COVID-19 Critical Care Consortium incorporating the ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease (ECMOCARD). The collaborative consists of investigators from the Asia-Pacific extracorporeal life support organization (APELSO) in collaboration with centers within the SPRINT-SARI and International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) Network. In Australia, this study is also supported by collaboration with the “National registry on the treatment and outcomes of patients requiring ECMO” (EXCEL Registry). A panel of 13 experts in neurocritical care was created in 2020 together with the main protocol of the COVID-19 Critical Care Consortium by the Steering committee of the consortium. The panel planned this subanalysis and the electronic case report form (eCRF) in February 2020 and followed it up through monthly meeting. The study will be conducted in compliance with the STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) (20) (Supplementary Item 1). Trial registration number: ACTRN12620000421932.

Objectives

The primary objective is to identify and describe the type and incidence of neurological complications in COVID-19 patients before and after admission to ICU, for all ICU patients selected patient subgroups (sex, age, country, treatment, COVID-19 wave).

Secondary objectives include: To evaluate the effect of neurological complications on outcomes after COVID-19, i.e., mortality, duration of ICU and hospital stay, neurological outcome (modified Rankin scale, mRS) at discharge, incidence of delirium and cognitive outcome at discharge. To identify factors related to the occurrence of neurological complications (including neurological injury due to the antiviral therapy).

Specific Sub-analysis

Secondary sub-analyses will also include the investigation of (1) magnetic resonance images (MRI) or computed tomography (CT) features; (2) serum biomarkers [neuronal injury markers (S100B, neuron specific enolase, NSE), endothelial dysfunction markers, inflammatory markers].

Inclusion and Exclusion Criteria

The COVID-19 Critical Care Consortium included all COVID-19 patients (≥18 years) admitted to ICU for receiving critical care with confirmed or suspected COVID-19 respiratory disease. For this specific sub-analysis, further inclusion criteria will be available data on neurological complications/manifestations. Patients treated with mechanical ventilation or ECMO for other causes than COVID-19 will be excluded.

Study Procedures and Setting

The protocol of the main study has been previously published (21). Participants in the COVID-19 Critical Care Consortium Observational Study are recruited at multiple sites in over 52 countries from 1st January 2020 onwards.

Data Collection

Data collection started from the commencement of COVID-19 pandemic and is planned to continue until completion of COVID-19 pandemic, as judged by the World Health Organization. According to the COVID-19 Critical Care Consortium Observational Study protocol (21) and neurological sub-study protocol, the following data will be collected: general patient characteristics, age, gender, body mass index (BMI), country, previous chronic comorbidities, scores of severity; premorbid scores [modified Rankin scale (0–6 points), Figure 1; new neurological complications, laboratory findings, imaging, and management of neurological complications (Supplementary Item 2); patient outcome (mortality at discharge, at 28-days, withdrawal of life-saving therapy and reason; mRS at ICU discharge, mRS at 28 days after discharge). Main eCRF of the COVID-19 critical care consortium study and neuro sub-study are provided in the Supplementary Items 3, 4.

Figure 1.

Figure 1

Modified Rankin Scale (mRS). The Modified Rankin Score (mRS) is a 6-point disability scale with possible scores ranging from 0 to 6 (from 0 = no symptoms to 6 = dead). A score of 0–3 indicate mild to moderate disability and a score of 4–5 indicate severe disability. From Wade (22).

Data Management

Data are stored in the central online eCRF database managed by the Oxford University in anonymized form, in order to preserve confidentiality of information in medical records. The Username and password will be assigned by the Oxford University during the registration process for individual Research Coordinators or Site Investigators. All electronic data transfer between study site and database will be username and password protected. The Participant List of the Neurology sub-study is maintained locally and is not to be transferred to any other location. confidentiality of the participant will be maintained unless disclosure is required by law.

Data entry and management will be coordinated by ISARIC and ECMOCARD steering committee, including programming and data management support. ANZIC-RC and ISARIC will act as custodian of the data. The University of Queensland (Australia) will receive data from the data custodians via data sharing agreements. The management committee of the trial will take responsibility for the content and integrity of any data.

Definition of Neurological Complications

Definition of neurological complications (2332) is listed in Table 1.

Table 1.

Definition of neurological complications/manifestations.

Neurological complication Definition
Central nervous system
Ischemic stroke (23) Neurological deficit due to an acute focal injury in the central nervous system caused by vascular involvement such as occlusion and cerebral infarction.
Intracranial hemorrhage (23, 24) Bleeding that occurs inside the skull. Hemorrhagic stroke: neurological deficit due to an acute focal injury in the central nervous system caused by vascular involvement with intracerebral or subarachnoid hemorrhage. Subdural hematoma: collection of blood under the dura mater.
Encephalitis/meningitis (25) Severe inflammatory disorder of the brain or meninges or parenchyma.
Transverse myelitis and other spinal cord pathologies (26) Inflammatory disorder with acute or subacute motor-sensory and autonomic spinal cord dysfunction.
Epilepsy, seizures, and generalized convulsive status epilepticus (27, 28) Epilepsy is a disorder of the brain characterized by an enduring predisposition to generate epileptic seizures, and by neurobiological, cognitive, psychological, and social consequences. Seizure is a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain. Generalized convulsive status epilepticus is defined in adults and children older than 5 years as ≥5 min of (1) continuous seizure or (2) two or more discrete seizures between which there is incomplete recovery of consciousness.
Delirium (29) Acute change in consciousness and attention caused by an organic condition.
Peripheral nervous system
Guillain-Barré Syndrome (30) Inflammatory immune-mediated polyradiculoneuropathy with acute onset that manifests with tingling, progressive weakness, autonomic disfunction and pain.
Critical illness myopathy/neuropathy (31) Neuromuscular weakness in the intensive care setting.
Hypogeusia/hyposmia (32) Quantitative disorders characterized by reduction of taste or smell.
Others
Hypoxic-ischemic brain injury (33) Reduction in blood supply, oxygen supply or utilization that determines a decreased oxygen delivery to the brain and post cardiac arrest hypoxic ischemic brain injury (reduction in blood supply, oxygen supply or utilization that determines a decreased oxygen delivery to the brain due to cardiac arrest).

Statistical Analysis Plan

Planned analyses will comprise of descriptive summaries and regression-based methods for estimating associations between patient-level variables, neurological complications, and outcomes. Descriptive statistics for summarizing the study cohort will be presented as medians with interquartile ranges and frequencies with percentages for continuous and categorical variables, respectively. As an observational study, missing data are expected; a data completeness summary will accompany descriptive summaries for all variables considered. The incidence of neurological complications will be calculated as the number of events per 1,000 ICU days and as the number of events divided by the total number of ICU admissions. Incidence will be estimated per complication using logistic and Poisson regression; Poisson models will include patient days as an offset to account for varying ICU exposure. Baseline models will be adjusted for patient-level variables (e.g., sex, age, country) and calendar time to account for the timing of different COVID-19 waves. Additional covariates will be informed by univariate analysis and penalized regression techniques to address the secondary objective related to incidence.

Analysis of associations between neurological complications and clinical outcomes will be examined using generalized linear mixed models for binary outcomes and parametric survival models for time-to-event outcomes. Evidence of potential associations, including patient demographics and clinical signs assessed during ICU admission, will initially be assessed using univariate analysis. Results of univariate analysis will be used to inform variable selection for multivariable analysis.

Multivariable models for all study objectives will be adjusted for known confounders as fixed or random effects, including study center, country, and calendar time. Model results will be presented as odds ratios (binary outcomes), relative risks (count outcomes) or hazard ratios (time-to-event outcomes) with 95% confidence intervals and p-values from hypothesis tests as appropriate.

Study Status

The protocol version is 1.2.8 of the COVID-19 Critical Care Consortium Observational Study available at https://www.elso.org/COVID19/ECMOCARD.aspx. Data collection started from the commencement of COVID-19 pandemic and is planned to continue until completion of COVID-19 pandemic, as judged by the World Health Organization, as reported in the protocol.

Discussion

This neurological sub-analysis of the COVID-19 Critical Care Consortium Observational Study is designed with the aim to obtain a detailed overview on neurological complications in a large international multicenter cohort of critically ill COVID-19 patients admitted to ICU, to determine incidence and risk factors of neurological complications, and the association of neurological complications with outcome. This study will provide real-time global data without geographic restrictions.

In the latest 2 years, knowledge has increased regarding extra-pulmonary complications of COVID-19 and their effect on outcome. Severe COVID-19 disease potentially involves multiple organs, including pulmonary, coagulation, cardiac, neurological, renal, hepatic, and gastrointestinal manifestations (34). Many neurological manifestations have been described recently in small observational studies, but additional evidence is needed from large multicentric cohorts. For this reason, in the present study we aim to depict the incidence, risk factors, and impact on outcome of neurological complications in critically ill COVID-19 patients from a large observational multicentric cohort. Data regarding pre-admission neurological manifestations, in-hospital neurological complications as well as ICU-and-hospital length of stay, neurological outcome (mRS), and mortality are available in the eCRF. This sub-analysis of the COVID-19 Critical Care Consortium Observational Study was pre-planned during the first/second wave of the pandemic (late 2020), thus increasing the data quality and minimizing the chance of spurious results and limiting the potential of exploratory learning. The number of patients included in the main study is continuously growing since the beginning of pandemic, allowing to obtain a large sample size, which can provide important information on the current incidence and characteristics of neurological manifestations in COVID-19 patients, evaluating potential associations between predictors and development of neurological complications, and assessing outcomes at discharge from ICU and from hospital and 28-days patients' outcomes. The included patients will be from different countries and centers, including low incoming countries. The patients will be also included during different waves and years of the pandemic, before and after the advent of vaccination campaigns, and with different variants of COVID-19 (i.e., omicron, delta, etc.). This will provide interesting insights on the differences in epidemiology, management strategies, geographical, and economical characteristics of COVID-19 adult patients who manifest neurological complications admitted to ICU. This global research context will provide the lens through which the study as well as its methodological approaches, findings, conclusions, and recommendations can be viewed.

Incidence and Types of Neurological Manifestations and Complications of COVID-19

The importance of investigating neurological manifestations in COVID-19, assessing their risk factors, and association with outcome is justified by the increasing identification in the available literature of many studies which reported high morbidity and mortality and poor neurological outcome in COVID-19 patients who manifest neurological complications, with the need for identifying and investigating such alterations in a bigger cohort of COVID-19 critically ill patients. Indeed, regarding each of the identified neurological manifestations of COVID-19, the data are fragmentary and come from different small cohorts. Myalgia, dysgeusia, and taste dysfunction were frequently reported (33% of cases), altered mental status in 32%, headache 29%, encephalopathy 26%, alteration of consciousness 13%, stroke 12%, dizziness 10%, vision impairment 6%, intracerebral hemorrhage, 5%, seizure 4%, encephalitis 2%, and GBS 1% (35). Intracranial hemorrhage was identified in 477 patients with a prevalence of 0.85% and a mortality of 52% suggesting a very poor prognosis despite rare incidence (36). The prevalence of intracranial hemorrhage, ischemic stroke, and hypoxic ischemic brain injury was higher in patients with COVID-19 who underwent ECMO support (5.9%) with a mortality of 92% (17). Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis have been reported in 46 patients with COVID-19 only, of whom 32% died (37).

Risk Factors for Neurological Manifestations and Complications of COVID-19

Regarding risk factors and association of neurological manifestations with outcome, a systematic review revealed that patients who suffer from a severe COVID-19 have more CNS involvement, neurological symptoms, and association with stroke. More severe patients had higher D-dimer and C-reactive protein levels than non-severe patients and presented multiple organ involvement (38). Myalgia, acute cerebrovascular disease, elevated creatin kinase, and lactate dehydrogenase were associated with more severe disease (3), while delirium on admission is a good predictor of mortality outcome in COVID-19 (39). In a cohort of 1,072 patients, age, headache at presentation, preexisting neurologic disease, invasive mechanical ventilation, and neutrophil/lymphocyte ratio ≥ 9 were independent predictors of new neurologic complications (40). In another study, the CT lung disease severity score was predictive of acute abnormalities on neuroimaging in patients with COVID-19 with neurologic manifestations (41). In a retrospective analysis, previous neurological history did not impact mortality, whereas new neurological manifestations were predictors of death (42). In a large cohort of 3,055 COVID-19 patients, preexisting neurological disorders were associated with higher risk of developing new neurological manifestations (2).

Outcome of COVID-19 Patients With Neurological Manifestations and Complications

Patients affected by COVID-19 with neurological manifestations were noted to have an impaired quality of life in 49% of cases, with a residual disability at 6-months in 52%, impaired cognition in 69%, and persistence of anxiety and depression in 32% (43). Neurological outcome in 135 patients with COVID-19 at 3-months follow-up was impaired (44), and a significant patient number still suffer from neurological sequelae 1 year after SARS-CoV-2 infection (45). A large multicentric study investigating delirium in 4,530 COVID-19 patients revealed that acute brain dysfunction was highly prevalent and prolonged in critically ill patients with COVID-19, with benzodiazepines and lack of family visitation identified to be risk factors for its development (46). After 6 months, in a cohort of 236,379 patients with COVID-19, neurological and psychiatric manifestations had an estimated incidence of 33.62 and 12.84%, respectively (47). Clinical outcome was evaluated in a cohort of 267 patients, concluding that patients with cerebrovascular disease had the worst prognosis (48).

Potential Pitfalls and Unintended Effects of This Study

Taken together, a large number of case reports and case series, despite coming mainly from small cohorts and local studies raise interest around the need for clarification about type and incidence of COVID-19 neurological manifestations, risk factors, and association with outcome on large scale, thus encouraging to better plan for possible management and therapeutics for neurological complications in critically ill COVID-19 patients. A limitation of current available data in the literature is that most of the data come from small cohorts, that could be addressed by using the larger COVID-19 Critical Care Consortium. Our study is unique in a way that we can address both limitations by studying the questions with international cohort with granular neurological variables. According to the design of our study, no unintended effects are expected. However, some limitations should be addressed. Being an observational study, it can be exposed to bias and confounding. Additionally, it cannot be used to demonstrate causality.

Conclusions

In conclusion the present study will provide new information on a global scale regarding the incidence and type of neurological complications, risk factors, and associated outcomes in COVID-19 with clinical applications.

Ethics Statement

The study will be conducted in compliance with the current version of the COVID-19 Critical Care Consortium and Neurologic sub-study protocol. Protocol version and subsequent amendment will be submitted and approved by the Local Ethics Committee in compliance to national standards. Sites wishing to participate will be required to provide the COVID-19 Critical Care Consortium Research Coordinator with an Institutional Review Board (IRB) approval certificate. The regulations of the COVID-19 Critical Care Consortium state that this study will not require individual patient consent as an observational study. Data of this study is already recorded as part of routine clinical care, therefore justifying participant enrolment using a waiver of consent. However, for any location that deems individual consent necessary, informed consent will be managed in accordance with the local regulations of each involved IRB. In particular, in patients who meet the inclusion/exclusion criteria, informed consent will be obtained directly from the patient, either before the study or retrospectively in case the patient is unconscious at the time of enrolment. If the patient is unable to provide a consent form upon admission, informed consent will be obtained by his/her next of kin.

Author Contributions

DB drafted the manuscript and planned the methodology and the outcomes. S-MC and CR revised the manuscript and supervised the methodology and outcomes. DB, LP, MGr, SH, JF, GW, DBP, RA, LD, EG, MA, VW, AN, SD, GS, BP, DK, EM, AA-F, S-SS, MP, MGi, GF, PP, AP, NW, GL, JS, CR, and S-MC helped in the revision and methodology and approved the final version. All authors contributed to the article and approved the submitted version.

Funding

This study was supported by the Bill & Melinda Gates Foundation, Grant number INV-034765; The University of Queensland; The Wesley Medical Research; The Prince Charles Hospital Foundation; The Health Research Board of Ireland. GL was a recipient of the BITRECS fellowship; the BITRECS project has received funding from the European Union's Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement no. 754550 and from the La Caixa Foundation (ID 100010434), under the agreement LCF/PR/GN18/50310006. JS was funded by the Advance Queensland fellowship program.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Glossary

Abbreviations

APELSO

Asia-Pacific extracorporeal life support organization

BMI

body mass index

CNS

central nervous system

COVID-19

Coronavirus disease 2019

CT

computed tomography

ECMO

extracorporeal membrane oxygenation

ECMOCARD

ExtraCorporeal Membrane Oxygenation for 2019 novel Coronavirus Acute Respiratory Disease

eCRF

electronic case report form

ICU

intensive care unit

IRB

institutional review board

ISARIC

International Severe Acute Respiratory and emerging Infection Consortium

MRI

magnetic resonance images

mRS

modified Rankin scale

NSE

neuron specific enolase

PNS

peripheral nervous system.

Appendix

Prefix/First Name/Last Name Site Name
Eugeni Roure
Marta Roure
The University of Queensland, Australia
Fatima Nasrallah The Queensland Brain Institute, The University of Queensland, St. Lucia, QLD, Australia
Katie McMahon School of Clinical Sciences and Centre for Biomedical Technologies, Queensland University of Technology, Brisbane, Queensland, Australia
Judith Bellapart Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
Fabio Silvio Taccone Erasmus Hospital, Free University of Brussels, Evere, Belgium
Tala Al-Dabbous
Huda Alfoudri
Mohammed Shamsah
Al Adan Hospital
Subbarao Elapavaluru
Ashley Berg
Christina Horn
Allegheny General Hospital
Yunis Mayasi Avera McKennan Hospital & University Health Centre
Stephan Schroll Barmherzige Bruder Regansburg
Dan Meyer
Jorge Velazco
Ludmyla Ploskanych
Wanda Fikes
Rohini Bagewadi
Marvin Dao
Haley White
Alondra Berrios Laviena
Ashley Ehlers
Maysoon Shalabi-McGuire
Trent Witt
Baylor Scott & White Health
Lorenzo Grazioli
Luca Lorini
Bergamo Hospital
E. Wilson Grandin
Jose Nunez
Tiago Reyes
Beth Israel Deaconess Medical Centre
Diarmuid O'Briain
Stephanie Hunter
Box Hill Hospital
Mahesh Ramanan
Julia Affleck
Caboolture Hospital
Hemanth Hurkadli Veerendra
Sumeet Rai
Josie Russell-Brown
Mary Nourse
Canberra Hospital
Mark Joseph
Brook Mitchell
Martha Tenzer
Carilion Clinic
Ryuzo Abe Chiba University Graduate School of Medicine
Hwa Jin Cho
In Seok Jeong
Chonnam National University Hospital
Nadeem Rahman
Vivek Kakar
Cleveland Clinic- Abu Dhabi
Nicolas Brozzi Cleveland Clinic - Florida
Omar Mehkri
Sudhir Krishnan
Abhijit Duggal
Stuart Houltham
Cleveland Clinic - Ohio
Jerónimo Graf Clinica Alemana De Santiago
Roderigo Diaz
Roderigo Orrego
Camila Delgado
Joyce González
Maria Soledad Sanchez
Michael Piagnerelli
Josefa Valenzuela Sarrazin
Clinica Las Condez
A/Prof. Gustavo Zabert
Lucio Espinosa
Paulo Delgado
Victoria Delgado
Clinica Pasteur National- University of Comahue
Diego Fernando Bautista Rincón
Angela Maria Marulanda Yanten
Melissa Bustamante Duque
Clinica Valle de Lilli
Daniel Brodie Medical ICU, Columbia College of Physicians and Surgeons, New-York-Presbyterian Hospital, NY, NY, USA
Alyaa Elhazmi
Abdullah Al-Hudaib
Dr Sulaiman Alhabib Medical Group – Research Center, Riyadh, Saudi Arabia
Maria Callahan Emory University Healthcare System
M. Azhari Taufik
Elizabeth Yasmin Wardoyo
Margaretha Gunawan
Nurindah S Trisnaningrum
Vera Irawany
Muhammad Rayhan
Fatmawati Hospital
Mauro Panigada
Antonio Pesenti
Alberto Zanella
Giacomo Grasselli
Sebastiano Colombo
Chiara Martinet
Gaetano Florio
Fondazione IRCCS Policlinico of Milan (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Massimo Antonelli
Simone Carelli
Domenico L. Grieco
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Motohiro Asaki Fujieda Municipal General Hospital
Kota Hoshino Fukuoka University
Leonardo Salazar
Mary Alejandra Mendoza Monsalve
Fundación Cardiovascular de Colombia
John Laffey
Bairbre McNicholas
David Cosgrave
Galway University Hospitals
Joseph McCaffrey
Allison Bone
Geelong Hospital
Yusuff Hakeem Glenfield Hospital
James Winearls
Mandy Tallott
Gold Coast University Hospital
David Thomson
Christel Arnold-Day
Jerome Cupido
Zainap Fanie
Malcom Miller
Lisa Seymore
Dawid van Straaten
Groote Schuur Hospital
Ali Ait Hssain
Jeffrey Aliudin
Al-Reem Alqahtani
Khoulod Mohamed
Ahmed Mohamed
Darwin Tan
Joy Villanueva
Ahmed Zaqout
Hamad General Hospital - Weill Cornell Medical College in Qatar
Ethan Kurtzman
Arben Ademi
Ana Dobrita
Khadija El Aoudi
Juliet Segura
Hartford HealthCare
Gezy Giwangkancana Hasan Sadikin Hospital (Adult)
Shinichiro Ohshimo Hiroshima University
Javier Osatnik Hospital Alemán
Anne Joosten Hospital Civil Marie Curie
Antoni Torres
Minlan Yang
Ana Motos
Hospital Clinic, Barcelona
Carlos Luna Hospital de Clínicas
Francisco Arancibia Hospital del Tórax
Virginie Williams
Alexandre Noel
Hospital du Sacre Coeur (Universite de Montreal)
Nestor Luque Hospital Emergencia Ate Vitarte
Marina Fantini Hospital Mater Dei
Ruth Noemi Jorge García
Enrique Chicote Alvarez
Hospital Nuestra Señora de Gracia
Anna Greti Hospital Puerta de Hierro
Adrian Ceccato Hospital Universitari Sagrat Cor
Angel Sanchez Hospital Universitario Sant Joan d'Alacant
Ana Loza Vazquez Hospital Universitario Virgen de Valme
Ferran Roche-Campo
Diego Franch-Llasat
Hospital Verge de la Cinta de Tortosa
Divina Tuazon Houston Methodist Hospital
Marcelo Amato
Luciana Cassimiro
Flavio Pola
Francis Ribeiro
Guilherme Fonseca
INCOR (Universidade de São Paulo)
Heidi Dalton
Mehul Desai
Erik Osborn
Hala Deeb
INOVA Fairfax Hospital
Antonio Arcadipane
Gennaro Martucci
Giovanna Panarello
Chiara Vitiello
Claudia Bianco
Giovanna Occhipinti
Matteo Rossetti
Raffaele Cuffaro
ISMETT
Sung-Min Cho
Glenn Whitman
Johns Hopkins
Hiroaki Shimizu
Naoki Moriyama
Kakogawa Acute Care Medical Center
Jae-Burm Kim Keimyung University Dong San Hospital
Nobuya Kitamura Kimitsu Chuo Hospital
Johannes Gebauer Klinikum Passau
Toshiki Yokoyama Kouritu Tousei Hospital
Abdulrahman Al-Fares
Sarah Buabbas
Esam Alamad
Fatma Alawadhi
Kalthoum Alawadi Al-Amiri and Jaber Al-Ahmed Hospitals, Kuwait Extracorporeal Life Support Program
Hiro Tanaka Kyoto Medical Centre
Satoru Hashimoto
Masaki Yamazaki
Kyoto Prefectural University of Medicine
Tak-Hyuck Oh Kyung Pook National University Chilgok Hospital
Mark Epler
Cathleen Forney
Louise Kruse
Jared Feister
Joelle Williamson
Katherine Grobengieser
Lancaster General Health
Eric Gnall
Sasha Golden
Mara Caroline
Timothy Shapiro
Colleen Karaj
Lisa Thome
Lynn Sher
Mark Vanderland
Mary Welch
Sherry McDermott
Lankenau Institute of Medical Research (Main Line Health)
Matthew Brain
Sarah Mineall
Launceston General Hospital
Dai Kimura Le Bonheur Children's Hospital
Luca Brazzi
Gabriele Sales
Giorgia Montrucchio
Le Molinette Hospital (Ospedale Molinette Torino)
Tawnya Ogston Legacy Emanuel Medical Center
Dave Nagpal
Karlee Fischer
London Health Sciences Centre
Roberto Lorusso Maastricht University Medical Centre
Rajavardhan Rangappa
Sujin Rai
Argin Appu
Manipal Hospital Whitefield
Mariano Esperatti
Nora Angélica Fuentes
Maria Eugenia Gonzalez
Hospital Privado de Comunidad. Mar del Plata. Escuela Superior de Medicina. Universidad Nacional de Mar del Plata
Diarmuid O'Briain Maroondah Hospital
Edmund G. Carton Mater Misericordiae University Hospital
Ayan Sen
Amanda Palacios
Deborah Rainey
Mayo Clinic College of Medicine
Gordan Samoukoviv
Josie Campisi
McGill University Health Centre
Lucia Durham
Emily Neumann
Cassandra Seefeldt
Octavio Falcucci
Amanda Emmrich
Jennifer Guy
Carling Johns
Kelly Potzner
Catherine Zimmermann
Angelia Espinal
Medical College of Wisconsin (Froedtert Hospital)
Nina Buchtele
Michael Schwameis
Andrea Korhnfehl
Roman Brock
Thomas Staudinger
Medical University of Vienna
Stephanie-Susanne Stecher
Michaela Barnikel
Sófia Antón
Alexandra Pawlikowski
Medical Department II, LMU Hospital Munich
Akram Zaaqoq
Lan Anh Galloway
Caitlin Merley
MedStar Washington Hospital Centre
Alistair Nichol Monash University
Marc Csete
Luisa Quesada
Isabela Saba
Mount Sinai Medical Centre
Daisuke Kasugai
Hiroaki Hiraiwa
Taku Tanaka Nagoya University Hospital
Eva Marwali
Yoel Purnama
Santi Rahayu Dewayanti
Ardiyan
Dafsah Arifa Juzar
Debby Siagian
National Cardiovascular Center Harapan Kita, Jakarta, Indonesia
Yih-Sharng Chen National Taiwan University Hospital
Mark Ogino Nemours Alfred I duPont Hospital for Children
Indrek Ratsep
Andra-Maris Post
Piret Sillaots
Anneli Krund
Merili-Helen Lehiste
Tanel Lepik
North Estonia Medical Centre
Frank Manetta
Effe Mihelis
Iam Claire Sarmiento
Mangala Narasimhan
Michael Varrone
Northwell Health
Mamoru Komats Obihiro-Kosei General Hospital
Julia Garcia-Diaz
Catherine Harmon
Ochsner Clinic Foundation
S. Veena Satyapriya
Amar Bhatt
Nahush A. Mokadam
Alberto Uribe
Alicia Gonzalez
Haixia Shi
Johnny McKeown
Joshua Pasek
Juan Fiorda
Marco Echeverria
Ohio State University Medical Centre
Rita Moreno Oklahoma Heart Institute
Bishoy Zakhary Oregon Health and Science University Hospital (OHSU)
Marco Cavana
Alberto Cucino
Ospedale di Arco (Trento Hospital)
Giuseppe Foti
Marco Giani
Benedetta Fumagalli
Ospedale San Gerardo
Davide Chiumello
Valentina Castagna
Ospedale San Paolo
Andrea Dell'Amore
Paolo Navalesi
Padua University Hospital (Policlinico of Padova)
Hoi-Ping Shum Pamela Youde Nethersole Eastern Hospital
Alain Vuysteke Papworth Hospitals NHS Foundation Trust
Asad Usman
Andrew Acker
Benjamin Smood
Blake Mergler
Federico Sertic
Madhu Subramanian
Alexandra Sperry
Nicolas Rizer
Penn Medicine (Hospital of the University of Pennsylvania)
Erlina Burhan
Menaldi Rasmin
Ernita Akmal
Faya Sitompul
Navy Lolong
Bhat Naivedh
Persahabatan General Hospital
Simon Erickson Perth Children's Hospital
Peter Barrett
David Dean
Julia Daugherty Piedmont Atlanta Hospital
Antonio Loforte Policlinico di S. Orsola, Università di Bologna
Irfan Khan
Mohammed Abraar Quraishi
Olivia DeSantis
Presbyterian Hospital Services, Albuquerque
Dominic So
Darshana Kandamby
Princess Margaret Hospital
Jose M. Mandei
Hans Natanael
Prof Dr R. D. Kandou General Hospital - Paediatric
Eka YudhaLantang
Anastasia Lantang
Prof Dr R. D R. D. Kandou General Hospital - Adult
Surya Oto Wijaya Dr Sulianti Saroso Hospital
Anna Jung Providence Saint John's Health Centre
George Ng
Wing Yiu Ng
Queen Elizabeth Hospital, Hong Kong
Pauline Yeung Ng
Shu Fang
The University of Hong Kong
Alexis Tabah
Megan Ratcliffe
Maree Duroux
Redcliffe Hospital
Shingo Adachi
Shota Nakao
Rinku General Medical Center (and Senshu Trauma and Critical Care Center)
Pablo Blanco
Ana Prieto
Jesús Sánchez
Rio Hortega University Hospital
Meghan Nicholson Rochester General Hospital
Warwick Butt
Alyssa Serratore
Carmel Delzoppo
Royal Children's Hospital
Pierre Janin
Elizabeth Yarad
Royal North Shore Hospital
Richard Totaro
Jennifer Coles
Royal Prince Alfred Hospital
Bambang Pujo RSUD Soetomo
Robert Balk
Andy Vissing
Esha Kapania
James Hays
Samuel Fox
Garrett Yantosh
Pavel Mishin
Rush University, Chicago
Saptadi Yuliarto
Kohar Hari Santoso
Susanthy Djajalaksana
Saiful Anwar Malang Hospital (Brawijaya University) (Paediatrics)
Arie Zainul Fatoni Saiful Anwar Malang Hospital (Brawijaya University) (Adult)
Masahiro Fukuda Saiseikai Senri Hospital
Keibun Liu Saiseikai Utsunomiya Hospital
Paolo Pelosi
Denise Battaglini
San Martino Hospital
Juan Fernando Masa Jiménez San Pedro de Alcantara Hospital
Diego Bastos Sao Camilo Cura D'ars
Sérgio Gaião São João Hospital Centre, Porto
Desy Rusmawatiningtyas Sardjito Hospital (Paediatrics)
Young-Jae Cho Seoul National University Bundang Hospital
Su Hwan Lee Severance Hospital
Tatsuya Kawasaki Shizuoka Children's Hospital
Laveena Munshi Sinai Health Systems (Mount Sinai Hospital)
Pranya Sakiyalak
Prompak Nitayavardhana
Siriraj Hospital
Tamara Seitz Sozialmedizinisches Zentrum Süd – Kaiser-Franz-Josef-Spital
Rakesh Arora
David Kent
St Boniface Hospital (University of Mannitoba)
Daniel Marino St Christopher's Hospital for Children
Swapnil Parwar
Andrew Cheng
Jennene Miller
St George Hospital
Shigeki Fujitani
Naoki Shimizu
St Marianna Medical University Hospital
Jai Madhok
Clark Owyang
Stanford University Hospital
Hergen Buscher
Claire Reynolds
St Vincent's Hospital
Olavi Maasikas
AleksanBeljantsev
Vladislav Mihnovits
Tartu University Hospital
Takako Akimoto
Mariko Aizawa
Kanako Horibe
Ryota Onodera
Teine Keijinkai Hospital
Carol Hodgson
Aidan Burrell
Meredith Young
The Alfred Hospital
Timothy George The Heart Hospital Baylor Plano, Plano
Kiran Shekar
Niki McGuinness
Lacey Irvine
The Prince Charles Hospital
Brigid Flynn The University of Kansas Medical Centre
Tomoyuki Endo Tohoku Medical and Pharmaceutical University
Kazuhiro Sugiyama Tokyo Metropolitan Bokutoh Hospital
Keiki Shimizu Tokyo Metropolitan Medical Center
Eddy Fan
Kathleen Exconde
Toronto General Hospital
Shingo Ichiba Tokyo Women's Medical University Hospital
Leslie Lussier Tufts Medical Centre (and Floating Hospital for Children)
Gösta Lotz Universitätsklinikum Frankfurt (University Hospital Frankfurt) (Uniklinik)
Maximilian Malfertheiner
Lars Maier
Esther Dreier
Universitätsklinikum Regensburg (Klinik für Innere Medizin II)
Neurinda Permata Kusumastuti University Airlangga Hospital (Paediatric)
Colin McCloskey
Al-Awwab Dabaliz
Tarek B Elshazly
Josiah Smith
University Hospital Cleveland Medical Centre (UH Cleveland Hospital)
Konstanty S. Szuldrzynski
Piotr Bielański
University Hospital in Krakow
Yusuff Hakeem University Hospitals of Leicester NHS Trust (Glenfield Hospital)
Keith Wille University of Alabama at Birmingham Hospital (UAB)
Srinivas Murthy University of British Columbia
Ken Kuljit S. Parhar
Kirsten M. Fiest
Cassidy Codan
Anmol Shahid
University of Calgary (Peter Lougheed Centre, Foothills Medical Centre, South Health Campus and Rockyview General Hospital)
Mohamed Fayed
Timothy Evans
Rebekah Garcia
Ashley Gutierrez
Hiroaki Shimizu
University of California, San Francisco-Fresno Clinical Research Centre
Tae Song
Rebecca Rose
University of Chicago
Suzanne Bennett
Denise Richardson
University of Cincinnati Medical Centre
Giles Peek University of Florida
Lovkesh Arora
Kristina Rappapport
Kristina Rudolph
Zita Sibenaller
Lori Stout
Alicia Walter
University of Iowa
Daniel Herr
Nazli Vedadi
University of Maryland - Baltimore
Robert Bartlett University of Michigan Medical Center
Antonio Pesenti University of Milan
Shaun Thompson Julie Hoffman
Xiaonan Ying
University of Nebraska Medical Centre
Ryan Kennedy University of Oklahoma Health Sciences Centre (OU)
Muhammed Elhadi Faculty of Medicine, University of Tripoli
Matthew Griffee
Anna Ciullo
Yuri Kida
University of Utah Hospital
Ricard Ferrer Roca
JordI Riera
Sofia Contreras
Cynthia Alegre
Vall d'Hebron University Hospital, Barcelona
Christy Kay
Irene Fischer
Elizabeth Renner
Washington University in St. Louis/ Barnes Jewish Hospital
Hayato Taniguci Yokohama City University Medical Center
John Fraser
Gianluigi Li Bassi
Jacky Suen
Adrian Barnett
Nicole White
Kristen Gibbons
Simon Forsyth
Amanda Corley
India Pearse
Samuel Hinton
Gabriella Abbate
Halah Hassan
Silver Heinsar
Varun A Karnik
Katrina Ki
Hollier F. O'Neill
Nchafatso Obonyo
Leticia Pretti Pimenta
Janice D. Reid
Kei Sato
Kiran Shekar
Aapeli Vuorinen
Karin S. Wildi
Emily S. Wilson
Stephanie Yerkovich
COVID-19 Critical Care Consortium
James Lee
Daniel Plotkin
Barbara Wanjiru Citarella
Laura Merson
ISARIC, Centre for Tropical Medicine and Global Health, University of Oxford, Oxford, UK

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2022.930217/full#supplementary-material

References

  • 1.Wong CKH, Wong JYH, Tang EHM, Au CH, Wai AKC. Clinical presentations, laboratory and radiological findings, and treatments for 11,028 COVID-19 patients: a systematic review and meta-analysis. Sci Rep. (2020) 10:19765. 10.1038/s41598-020-74988-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Chou SH-Y, Beghi E, Helbok R, Moro E, Sampson J, Altamirano V, et al. Global incidence of neurological manifestations among patients hospitalized with COVID-19—a report for the GCS-NeuroCOVID consortium and the ENERGY consortium. JAMA Netw Open. (2021) 4:e2112131. 10.1001/jamanetworkopen.2021.12131 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Yassin A, Nawaiseh M, Shaban A, Alsherbini K, El-Salem K, Soudah O, et al. Neurological manifestations and complications of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. BMC Neurol. (2021) 21:138. 10.1186/s12883-021-02161-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Huth SF, Cho S-M, Robba C, Highton D, Battaglini D, Bellapart J, et al. Neurological manifestations of coronavirus disease 2019: a comprehensive review and meta-analysis of the first 6 months of pandemic reporting. Front Neurol. (2021) 12:664599. 10.3389/fneur.2021.664599 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Misra S, Kolappa K, Prasad M, Radhakrishnan D, Thakur KT, Solomon T, et al. Frequency of neurologic manifestations in COVID-19. Neurology. (2021) 97:e2269–81. 10.1212/WNL.0000000000012930 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Battaglini D, Brunetti I, Anania P, Fiaschi P, Zona G, Ball L, et al. Neurological manifestations of severe SARS-CoV-2 infection: potential mechanisms and implications of individualized mechanical ventilation settings. Front Neurol. (2020) 11:845. 10.3389/fneur.2020.00845 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Sashindranath M, Nandurkar HH. Endothelial dysfunction in the brain. Stroke. (2021) 52:1895–904. 10.1161/STROKEAHA.120.032711 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Savarraj J, Park ES, Colpo GD, Hinds SN, Morales D, Ahnstedt H, et al. Brain injury, endothelial injury and inflammatory markers are elevated and express sex-specific alterations after COVID-19. J Neuroinflammation. (2021) 18:277. 10.1186/s12974-021-02323-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Krasemann S, Haferkamp U, Pfefferle S, Woo MS, Heinrich F, Schweizer M, et al. The blood-brain barrier is dysregulated in COVID-19 and serves as a CNS entry route for SARS-CoV-2. Stem Cell Rep. (2022) 17:307–20. 10.1016/j.stemcr.2021.12.011 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Abbas Z, Chaudhary A. COVID-19 associated coagulopathy resulting in cerebral venous thrombosis and pulmonary embolism. Cureus. (2021) 13:e19602. 10.7759/cureus.19602 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Manolis AS, Manolis TA, Manolis AA, Papatheou D, Melita H. COVID-19 infection: viral macro- and micro-vascular coagulopathy and thromboembolism/prophylactic and therapeutic management. J Cardiovasc Pharmacol Ther. (2021) 26:12–24. 10.1177/1074248420958973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Robba C, Battaglini D, Ball L, Valbusa A, Porto I, Della Bona R, et al. Coagulative disorders in critically ill COVID-19 patients with acute distress respiratory syndrome: a critical review. J Clin Med. (2021) 10:140. 10.3390/jcm10010140 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Waldrop G, Safavynia SA, Barra ME, Agarwal S, Berlin DA, Boehme AK, et al. Prolonged unconsciousness is common in COVID-19 and associated with hypoxemia. Ann Neurol. (2022) 91:740–55. 10.1002/ana.26342 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Rutkai I, Mayer MG, Hellmers LM, Ning B, Huang Z, Monjure CJ, et al. Neuropathology and virus in brain of SARS-CoV-2 infected non-human primates. Nat Commun. (2022) 13:1745. 10.1038/s41467-022-29440-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Ambade V, Ambade S. SARS-CoV-2 infecting endothelial cells, biochemical alterations, autopsy findings and outcomes in COVID-19, suggest role of hypoxia-inducible factor-1. J Med Biochem. (2022) 41:14–20. 10.5937/jomb0-30659 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Chen J, Tan R, Mo Y, Zhang J. The blood-brain barrier in health, neurological diseases, and COVID-19. Fundam Res. (2022). 10.1016/j.fmre.2022.03.003. [Epub ahead of print]. [DOI] [Google Scholar]
  • 17.Kannapadi N V., Jami M, Premraj L, Etchill EW, Giuliano K, Bush EL, et al. Neurological complications in COVID-19 patients with ECMO support: a systematic review and meta-analysis. Hear Lung Circ. (2022) 31:292–8. 10.1016/j.hlc.2021.10.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Frontera JA, Yang D, Lewis A, Patel P, Medicherla C, Arena V, et al. A prospective study of long-term outcomes among hospitalized COVID-19 patients with and without neurological complications. J Neurol Sci. (2021) 426:117486. 10.1016/j.jns.2021.117486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Davidescu EI, Odajiu I, Tulbǎ D, Sandu CD, Bunea T, Sandu G, et al. Prognostic factors in COVID-19 patients with new neurological manifestations: a retrospective cohort study in a romanian neurology department. Front Aging Neurosci. (2021) 13:645611. 10.3389/fnagi.2021.645611 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. (2007) 370:1453–7. 10.1016/S0140-6736(07)61602-X [DOI] [PubMed] [Google Scholar]
  • 21.Li Bassi G, Suen J, Barnett AG, Corley A, Millar J, Fanning J, et al. Design and rationale of the COVID-19 critical care consortium international, multicentre, observational study. BMJ Open. (2020) 10:e041417. 10.1136/bmjopen-2020-041417 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Wade DT. Measurement in Neurological Rehabilitation. New York, NY: Oxford University Press; (1992). [PubMed] [Google Scholar]
  • 23.Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, (Buddy), Culebras A, et al. An updated definition of stroke for the 21st century. Stroke. (2013) 44:2064–89. 10.1161/STR.0b013e318296aeca [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Stone JL, Rifai MHS, Sugar O, Lang RGR, Oldershaw JB, Moody RA. Subdural hematomas. Surg Neurol. (1983) 19:216–31. 10.1016/S0090-3019(83)80005-6 [DOI] [PubMed] [Google Scholar]
  • 25.Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. (2016) 15:391–404. 10.1016/S1474-4422(15)00401-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Rodríguez Y, Rojas M, Pacheco Y, Acosta-Ampudia Y, Ramírez-Santana C, Monsalve DM, et al. Guillain–Barré syndrome, transverse myelitis and infectious diseases. Cell Mol Immunol. (2018) 15:547–62. 10.1038/cmi.2017.142 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Fisher RS, Boas W van E, Blume W, Elger C, Genton P, Lee P, et al. Epileptic seizures and epilepsy: definitions proposed by the international league against epilepsy (ILAE) and the international bureau for epilepsy (IBE). Epilepsia. (2005) 46:470–2. 10.1111/j.0013-9580.2005.66104.x [DOI] [PubMed] [Google Scholar]
  • 28.Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia. (1999) 40:120–2. 10.1111/j.1528-1157.1999.tb02000.x [DOI] [PubMed] [Google Scholar]
  • 29.Setters B, Solberg LM. Delirium. Prim Care. (2017) 44:541–59. 10.1016/j.pop.2017.04.010 [DOI] [PubMed] [Google Scholar]
  • 30.Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician. (2013) 87:191–7. [PubMed] [Google Scholar]
  • 31.Gutmann L, Gutmann L. Critical illness neuropathy and myopathy. Arch Neurol. (1999) 56:527. 10.1001/archneur.56.5.527 [DOI] [PubMed] [Google Scholar]
  • 32.Finsterer J, Stollberger C. Causes of hypogeusia/hyposmia in SARS-CoV2 infected patients. J Med Virol. (2020) 92:1793–4. 10.1002/jmv.25903 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sekhon MS, Ainslie PN, Griesdale DE. Clinical pathophysiology of hypoxic ischemic brain injury after cardiac arrest: a “two-hit” model. Crit Care. (2017) 21:90. 10.1186/s13054-017-1670-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Robba C, Battaglini D, Pelosi P, Rocco RMP. Multiple organ dysfunction in SARS-CoV-2: MODS-CoV-2. Expert Rev Respir Med. (2020) 14:865–8. 10.1080/17476348.2020.1778470 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.He Y, Bai X, Zhu T, Huang J, Zhang H. What can the neurological manifestations of COVID-19 tell us: a meta-analysis. J Transl Med. (2021) 19:363. 10.1186/s12967-021-03039-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Schmidbauer ML, Ferse C, Salih F, Klingner C, Musleh R, Kunst S, et al. COVID-19 and intracranial hemorrhage: a multicenter case series, systematic review and pooled analysis. J Clin Med. (2022) 11:605. 10.3390/jcm11030605 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Manzano GS, McEntire CRS, Martinez-Lage M, Mateen FJ, Hutto SK. Acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalitis following COVID-19. Neurol Neuroimmunol Neuroinflammation. (2021) 8:e1080. 10.1212/NXI.0000000000001080 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Severo Bem Junior L, do Rego Aquino PL, Nunes Rabelo N, do Rego Aquino MA, Veiga Silva AC, Ferreira Valenca Mota R de C, et al. SARS-CoV-2 and nervous system - neurological manifestations in patients with COVID-19: a systematic review. J Neurol Res. (2020) 10:113–21. 10.14740/jnr602 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Hariyanto TI, Putri C, Hananto JE, Arisa J, Fransisca V Situmeang R, Kurniawan A. Delirium is a good predictor for poor outcomes from coronavirus disease 2019 (COVID-19) pneumonia: a systematic review, meta-analysis, and meta-regression. J Psychiatr Res. (2021) 142:361–8. 10.1016/j.jpsychires.2021.08.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Flores-Silva FD, García-Grimshaw M, Valdés-Ferrer SI, Vigueras-Hernández AP, Domínguez-Moreno R, Tristán-Samaniego DP, et al. Neurologic manifestations in hospitalized patients with COVID-19 in Mexico City. PLoS ONE. (2021) 16:e0247433. 10.1371/journal.pone.0247433 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Mahammedi A, Ramos A, Bargalló N, Gaskill M, Kapur S, Saba L, et al. Brain and lung imaging correlation in patients with COVID-19: could the severity of lung disease reflect the prevalence of acute abnormalities on neuroimaging? A global multicenter observational study. Am J Neuroradiol. (2021) 42:1008–16. 10.3174/ajnr.A7072 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Salahuddin H, Afreen E, Sheikh IS, Lateef S, Dawod G, Daboul J, et al. Neurological predictors of clinical outcomes in hospitalized patients with COVID-19. Front Neurol. (2020) 11:585944. 10.3389/fneur.2020.585944 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Chaumont H, Meppiel E, Roze E, Tressières B, de Broucker T, Lannuzel A. Long-term outcomes after NeuroCOVID: a 6-month follow-up study on 60 patients. Rev Neurol. (2022) 178:137–43. 10.1016/j.neurol.2021.12.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Rass V, Beer R, Schiefecker AJ, Kofler M, Lindner A, Mahlknecht P, et al. Neurological outcome and quality of life 3 months after COVID-19: a prospective observational cohort study. Eur J Neurol. (2021) 28:3348–59. 10.1111/ene.14803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Rass V, Beer R, Schiefecker AJ, Lindner A, Kofler M, Ianosi BA, et al. Neurological outcomes 1 year after COVID-19 diagnosis: a prospective longitudinal cohort study. Eur J Neurol. (2022) 29:1685–96. 10.1111/ene.15307 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Pun BT, Badenes R, Heras La Calle G, Orun OM, Chen W, Raman R, et al. Prevalence and risk factors for delirium in critically ill patients with COVID-19 (COVID-D): a multicentre cohort study. Lancet Respir Med. (2021) 9:239–50. 10.1016/S2213-2600(20)30552-X [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Taquet M, Geddes JR, Husain M, Luciano S, Harrison PJ. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. (2021) 8:416–27. 10.1016/S2215-0366(21)00084-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Ross Russell AL, Hardwick M, Jeyanantham A, White LM, Deb S, Burnside G, et al. Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Commun. (2021) 3:fcab168. 10.2139/ssrn.3767901 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials


Articles from Frontiers in Medicine are provided here courtesy of Frontiers Media SA

RESOURCES